Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Kronos Bio, Inc. Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy September 25, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer September 23, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Participation in Medical and Investor Conferences in September September 03, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update August 08, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer July 23, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events May 22, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer May 21, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Reports First-Quarter 2024 Financial Results May 09, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results March 21, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway March 07, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting March 05, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference February 27, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement January 25, 2024 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate December 18, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference December 04, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference November 27, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results November 13, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study November 02, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting November 02, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting October 27, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC October 13, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 October 04, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development August 17, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results August 08, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance June 06, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Announces Participation in Upcoming Investor Conferences June 01, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results May 10, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors April 24, 2023 From Kronos Bio, Inc. Via GlobeNewswire Tickers KRON Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.